Login / Signup

Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study.

Lisa J T SmitsRenske Wilhelmina Maria PauwelsW KievitD J de JongA C de VriesF HoentjenC J van der Woudenull null
Published in: BMJ open (2020)
EudraCT registry (2016-003321-42); Clinicaltrials.gov registry (NCT03172377); Dutch trial registry (NTRID6417).
Keyphrases
  • study protocol
  • clinical trial
  • randomized controlled trial
  • ejection fraction
  • newly diagnosed
  • open label
  • prognostic factors
  • phase iii
  • phase ii
  • ulcerative colitis
  • disease activity